Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Merck
Boehringer Ingelheim
Medtronic
AstraZeneca

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Etrolizumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Etrolizumab: Sponsors, patents, clinical trial progress

Etrolizumab is an investigational drug.

There have been 12 clinical trials for Etrolizumab. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Ulcer, Colitis, Ulcerative, and Colitis. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and [disabled in preview].

There are five US patents protecting this investigational drug and fifty-nine international patents.

Recent Clinical Trials for Etrolizumab
TitleSponsorPhase
A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's DiseaseHoffmann-La RochePhase 1
A Study to Investigate the Comparability of Pharmacokinetics of Etrolizumab Administered Subcutaneously (SC) by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)Genentech, Inc.Phase 1
A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy ParticipantsGenentech, Inc.Phase 1

See all Etrolizumab clinical trials

Clinical Trial Summary for Etrolizumab

Top disease conditions for Etrolizumab
Top clinical trial sponsors for Etrolizumab

See all Etrolizumab clinical trials

US Patents for Etrolizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Etrolizumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Etrolizumab   Start Trial Methods for diagnosing and treating inflammatory bowel disease GENENTECH, INC. (South San Francisco, CA)   Start Trial
Etrolizumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
Etrolizumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Etrolizumab   Start Trial Methods for diagnosing and treating inflammatory bowel disease Genentech, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Etrolizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Etrolizumab Australia 2013220749 2032-02-15   Start Trial
Etrolizumab Brazil 112014019627 2032-02-15   Start Trial
Etrolizumab Canada 2862476 2032-02-15   Start Trial
Etrolizumab China 104114705 2032-02-15   Start Trial
Etrolizumab China 108570468 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Moodys
Merck
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.